Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors

Spotlight On: Much needed momentum for Sanofi?


In a week of major new drug approvals, one company arguably has more to gain than its competitors. Last Tuesday, the FDA approved Dupixent, a first-in-class treatment for moderate-to-severe atopic dermatitis; the latest product to emerge from Regeneron and Sanofi’s R&D pact. Regeneron is widely acknowledged as the heavy lifter on innovation in this relationship, while Sanofi provides much of the financial muscle. The French company is now desperate for a return on its investment.

Source: firstwordpharma.com

Back to the list

Invite partners to the exhibition
Facebook Youtube RSS Feed

Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34